Education
About Us
Working with TipRanks
Follow Us
Carisma Therapeutics, Inc. (CARM)
:CARM
CARM Analyst Ratings
Moderate Buy
1 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CARM Stock 12 Month Forecast
Average Price Target
$1.00
▲(127.27%Upside)
| Highest Price Target$1.00 | Average Price Target$1.00 | Lowest Price Target$1.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$0.5
Hold
13.64%
Upside
Reiterated
06/21/25
BTIG
―
Hold
―
Reiterated
04/01/25
D. Boral Capital
$12→$1
Buy
127.27%
Upside
Reiterated
04/01/25
Evercore ISI
$0.7
Hold
59.09%
Upside
Assigned
12/11/24
Capital One Financial
$7
Buy
1490.91%
Upside
Reiterated
08/09/24
We believe the next significant catalyst for the stock will be at YE24 when initial monotherapy data will be disclosed from the CT-0525 program. The update will be critical to show proof-of-concept, which is that greater cell yield and, thus, greater delivery of cells via monocytes (10 billion vs ~2 billion), can generate improved responses over CT-0508. While CT-0508 has shown some initial signals of activity in HER2 3+ patients with an average of 1.7 billion cells, best response to date with CT-0508 has been stable disease per RECIST (ORR 29%, n=14). Note, CARM dosed the first patient with CT-0525 in May. CT-0525 also has the FDA.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$0.5
Hold
13.64%
Upside
Reiterated
06/21/25
BTIG
―
Hold
―
Reiterated
04/01/25
D. Boral Capital
$12→$1
Buy
127.27%
Upside
Reiterated
04/01/25
Evercore ISI
$0.7
Hold
59.09%
Upside
Assigned
12/11/24
Capital One Financial
$7
Buy
1490.91%
Upside
Reiterated
08/09/24
We believe the next significant catalyst for the stock will be at YE24 when initial monotherapy data will be disclosed from the CT-0525 program. The update will be critical to show proof-of-concept, which is that greater cell yield and, thus, greater delivery of cells via monocytes (10 billion vs ~2 billion), can generate improved responses over CT-0508. While CT-0508 has shown some initial signals of activity in HER2 3+ patients with an average of 1.7 billion cells, best response to date with CT-0508 has been stable disease per RECIST (ORR 29%, n=14). Note, CARM dosed the first patient with CT-0525 in May. CT-0525 also has the FDA.
Best Analysts Covering Carisma Therapeutics
1 Month
xxx
Success Rate
1/6 ratings generated profit
Average Return
-13.63%
reiterated a xxx
rating 11 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 16.67% of your transactions generating a profit, with an average return of -13.63% per trade.
3 Months
xxx
Success Rate
1/6 ratings generated profit
Average Return
-25.07%
reiterated a xxx
rating 11 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 16.67% of your transactions generating a profit, with an average return of -25.07% per trade.
1 Year
Success Rate
0/6 ratings generated profit
Average Return
-76.05%
reiterated a buy rating 11 months ago
Copying Naureen Quibria's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -76.05% per trade.
2 Years
xxx
Success Rate
0/6 ratings generated profit
Average Return
-73.40%
reiterated a xxx
rating 11 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -73.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CARM Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Apr 25
May 25
Strong Buy
6
7
6
3
1
Buy
0
0
0
0
0
Hold
0
4
5
7
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
11
11
10
5
Each month's total comprises the sum of three months' worth of ratings.
CARM Financial Forecast
CARM Stock Forecast FAQ
What is CARM’s average 12-month price target, according to analysts?
Based on analyst ratings, Carisma Therapeutics, Inc.’s 12-month average price target is 1.00.
What is CARM’s upside potential, based on the analysts’ average price target?
Carisma Therapeutics, Inc. has 127.27% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CARM a Buy, Sell or Hold?
Carisma Therapeutics, Inc. has a consensus rating of Moderate Buy which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.
What is Carisma Therapeutics, Inc.’s price target?
The average price target for Carisma Therapeutics, Inc. is 1.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1.00 ,the lowest forecast is $1.00. The average price target represents 127.27% Increase from the current price of $0.44.
The highest analyst price target is $1.00 ,the lowest forecast is $1.00. The average price target represents 127.27% Increase from the current price of $0.44.
What do analysts say about Carisma Therapeutics, Inc.?
Carisma Therapeutics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of CARM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.